InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Goldberg Mark Alan, Director. Director active across 3 companies, notably Glycomimetics INC. In total, 17 reports have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €270k. History available since 18 May 2021. The latest transaction was disclosed on 18 June 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Goldberg Mark Alan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations17 total
3,902 sharesCommon StockSEC:0001104659-25-069384:0
3,902 shares@ US$128.1261.7% of flowCommon StockSEC:0001415889-25-018084:0
2,242 shares0Common StockSEC:0001415889-24-016981:0
4,584 shares@ US$3.0033.4% of flowCommon StockSEC:0001415889-24-009744:0
60,720 sharesCommon StockSEC:0001104659-24-014708:0
569 shares@ US$29.657.6% of flowCommon StockSEC:0001415889-24-000376:0
5,827 shares@ US$2.3632.5% of flowCommon stockSEC:0001209191-24-000067:0
10,000 shares@ US$14.7069.1% of flowCommon StockSEC:0001415889-23-014675:0
9,167 shares@ US$1.5034.1% of flowCommon stockSEC:0001209191-23-051449:0
1,063 shares@ US$15.877.9% of flowCommon StockSEC:0001415889-23-013757:0
894 shares@ US$18.877.7% of flowCommon StockSEC:0001415889-23-010821:0
2,600 shares0Common StockSEC:0001415889-23-010263:0
4,394 shares@ US$3.847.7% of flowCommon StockSEC:0001415889-23-006057:0
2,600 shares0Common StockSEC:0001415889-22-007131:0
5,000 shares@ US$59.9838.3% of flowCommon StockSEC:0001415889-22-002653:0
Canonical exit: 1 Jun 2022 (T+90)
2,250 shares0Common StockSEC:0001179110-21-006420:0
5,250 shares0Common StockSEC:0001209191-21-036378:0
17 of 17 declarations
About Goldberg Mark Alan
Mark Alan Goldberg is Administrateur of Blueprint Medicines Corp, ImmunoGen, Inc. and Glycomimetics INC. He has 17 filings, and across the 17 sampled filings the buy transactions amount to EUR 269880, with no sell transactions, covering the period from 2021-05-27 to 2025-07-21. The most frequent transaction nature is Attribution.
